The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. In 2025, Agenus sold their CDMO business to Zydus Lifesciences and partnered with Zydus to commercialize their molecules in India.
Cyborg Score Rationale
Agenus has strong partnerships and a diversified pipeline in high-value oncology markets, but faces clinical and regulatory challenges. The stock reached its all-time low of 1.38 USD in April 2025, reflecting recent headwinds from setbacks and restructuring efforts.
Top Insights
In August 2023, the company underwent strategic restructuring with a 25% workforce reduction and suspension of most non-BOT/BAL programs, intended to reduce annual operating expenses by approximately $40 million
Agenus is the sole US-manufacturer of QS-21, a key component in Oxford-AstraZeneca and Novavax COVID-19 vaccines, with supplies tightly controlled under the US Defence Production Act
Lead program AGEN1181 is in Phase 2 trials for metastatic colorectal cancer, pancreatic cancer, and melanoma
Analyst price targets range from $6.00 to $23.00 USD
Named Competitors
Checkpoint inhibitors — Major pharma developing competing PD-1, CTLA-4, and other checkpoint modulator therapies
CAR-T and cell therapies — Adoptive cell therapy competitors to MiNK Therapeutics platform
Cancer vaccine platforms — Competing personalized and off-the-shelf cancer vaccine approaches
Recent Developments
(January 2026) Closed strategic collaboration with Zydus Lifesciences for CDMO asset sale and India commercialization
(2025) Divested CDMO business including manufacturing sites in Emeryville and Berkeley
(March 2026) CEO participating in Leerink Global Biopharma Conference investor presentations
Open the full interactive Agenus Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.